FDA.reportPublic FDA data

PRIORIX vaccine 0.5 ML Injection

RxCUI
2603514
RxNorm name
PRIORIX vaccine 0.5 ML Injection
Display name
PRIORIX vaccine 0.5 ML Injection
Full name
PRIORIX vaccine 0.5 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:09

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125748PRIORIXMeasles, Mumps and Rubella Vaccine Live351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
95c6fdb6-b587-4413-92f9-d592b9f7a23ePRIORIX vaccine 0.5 ML InjectionPSN7These highlights do not include all the information needed to use PRIORIX safely and effectively. See full prescribing information for PRIORIX. PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) for injectable suspension, for subcutaneous use Initial U.S. Approval: 202220251114
95c6fdb6-b587-4413-92f9-d592b9f7a23ePriorix Measles, Mumps, and Rubella Virus Vaccine Live 0.5 ML InjectionSY7These highlights do not include all the information needed to use PRIORIX safely and effectively. See full prescribing information for PRIORIX. PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) for injectable suspension, for subcutaneous use Initial U.S. Approval: 202220251114
95c6fdb6-b587-4413-92f9-d592b9f7a23e0.5 ML measles virus vaccine live, attenuated Schwarz strain 5024 UNT/ML / mumps virus vaccine live, RIT-4385 strain 31684 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 3990 UNT/ML Injection [Priorix]SBD7These highlights do not include all the information needed to use PRIORIX safely and effectively. See full prescribing information for PRIORIX. PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) for injectable suspension, for subcutaneous use Initial U.S. Approval: 202220251114